2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-163883
    BChE-IN-34 2215768-12-8 98%
    BChE-IN-34 is a potent and selective butyrylcholinesterase (BChE) inhibitor with an IIC50 of 25 nM. BChE-IN-34 shows excellent selectivity against BChE over acetylcholinesterase. BChE-IN-34 has neuroprotective and antioxidant effects.
    BChE-IN-34
  • HY-163885
    SSZ 1262287-23-9 98%
    SSZ is a multi-target inhibitor, which targets multiple pathological mechanisms of Alzheimer's disease (AD). SSZ targets acetylcholinesterase, butyrylcholinesterase, β-site amyloid precursor protein cleavage enzyme 1 (BACE1), and γ-secretase. SSZ ameliorates Alzheimer’s diseases and exhibits neuroprotective effect in mice.
    SSZ
  • HY-163895
    δ opioid receptor antagonist 1 98%
    δ opioid receptor antagonist 1 (compound 6-Cy3) is a fluorescent antagonist probe with high selectivity for δ opioid receptor (DOR) (Ki=1.7 nM). δ opioid receptor antagonist 1 can be used to study the mechanism of pain perception.
    δ opioid receptor antagonist 1
  • HY-163909
    AChE-IN-72 98%
    AChE-IN-72 (Compound 13a) is an inhibitor for acetylcholinesterase (AChE) with an IC50 of 0.59 μM. AChE-IN-72 inhibits BChE with an IC50 of 5.02 μM. AChE-IN-72 exhibits radical scavenging with IC50 of 5.88 μM. AChE-IN-72 exhibits iron-chelating property, inhibits Aβ1−42 aggregation, and inhibits NLRP3 inflammasome activation. AChE-IN-72 ameliorates memory impairment in Betaine (HY-B0710)-induced AD mouse model. AChE-IN-72 is blood-brain barrier (BBB) penetrable.
    AChE-IN-72
  • HY-163916
    SalA-VS-07 2445895-33-8 98%
    SalA-VS-07 is a G protein-biased partial agonist for the Kappa-opioid receptor (KOR). SalA-VS-07 can be used for research of pain and other disorders.
    SalA-VS-07
  • HY-163917
    SalA-VS-08 2439152-14-2 98%
    SalA-VS-08 is a full agonist of kappa-opioid receptor (KOR) with selectivity and G-protein bias. SalA-VS-08 can be used in the research of analgesia.
    SalA-VS-08
  • HY-163974
    MRS7292 2092913-97-6 98%
    MRS7292 is a non-competitive inhibitor of human dopamine transporter (hDAT). MRS7292 inhibits dopamine transport.
    MRS7292
  • HY-163978
    YGZ-331 1350113-04-0 98%
    YGZ-331 is a sedative with a calming effect. YGZ-331 is a derivative of the adenosine nucleoside NGBA, which can increase GABA levels. YGZ-331 exerts a sedative-hypnotic effect by activating A1R and A2aR, and inhibiting CaMKII phosphorylation (pCaMKII) levels. YGZ-331 can reduce the spontaneous motor activity of mice.
    YGZ-331
  • HY-164083
    GR65630 113140-33-3 98%
    GR65630 is a potent and selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist. GR65630 can be used to study the expression patterns of 5-HT3 receptors in different brain regions and their possible functions in the central nervous system. GR65630 and its radiolabeled form [3H]GR65630 can be used to study the distribution, density and affinity of the receptors.
    GR65630
  • HY-164290
    Rhodady C10 1367579-04-1 98%
    Rhodady C10 (Compound C10) is a dynamin I GTPase inhibitor. Rhodady C10 blocks receptor-mediated endocytosis (IC50: 7 μM). Dynamin is involved in clathrin-independent endocytosis, phagocytosis, and caveolae internalization.
    Rhodady C10
  • HY-164311
    GPR17 modulator-1 3039853-91-0 98%
    GPR17 modulator-1 (Compound 2-046) is a modulator for G protein-coupled receptor 17 GPR17, with an IC50<10 nM for hGPR17 in CHO. GPR17 modulator-1 exhibits moderate pharmacokinetic characteristics in mice. GPR17 modulator-1 ix blood-brain barrier (BBB) permeable.
    GPR17 modulator-1
  • HY-164341
    TAU-IN-2 1417823-63-2 98%
    TAU-IN-2 (Example 25) is a TAU inhibitor with an EC50 value of 7.7 nM. TAU-IN-2 can be used in the study of neurodegenerative diseases.
    TAU-IN-2
  • HY-164417
    Kv7.2/Kv7.3 activator-1 2376398-43-3 98%
    Kv7.2/Kv7.3 activator-1 (compound 517) is a potent Kv7.2/Kv7.3 channel activator with an EC50 value of ＜1 µM. Kv7.2/Kv7.3 activator-1 has the potential for the research of neurological diseases.
    Kv7.2/Kv7.3 activator-1
  • HY-164505
    NRMA-9 2375659-16-6 98%
    NRMA-9 is the amide produrg of the small molecule nuclear receptor modulator. NRMA-9 exhibits a higher exposure in the brain, indicating that a good blood-brain barrier (BBB) penetration. NRMA-9 can be used for research of central nervous system diseases related to nuclear receptors, such as Alzheimer's disease and Parkinson's disease.
    NRMA-9
  • HY-164507
    NRMA-7 2375659-14-4 98%
    NRMA-7 is a BBB-penetrable small molecule nuclear receptor modulator. NRMA-7 can be used in the study of central nervous system diseases.
    NRMA-7
  • HY-164512
    NRMA-I 1417653-47-4 98%
    NRMA-I is the amide produrg of the small molecule nuclear receptor modulator. NRMA-I exhibits a higher exposure in the brain, indicating that a good blood-brain barrier (BBB) penetration. NRMA-I can be used for research of central nervous system diseases related to nuclear receptors, such as Alzheimer's disease and Parkinson's disease.
    NRMA-I
  • HY-164703
    Lumateperone metabolite 1 1469777-40-9 98%
    Lumateperone metabolite 1 (Formula T) is a metabolite of Lumateperone (HY-17637). Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator
    Lumateperone metabolite 1
  • HY-164795
    SBI-810 1849603-79-7 98%
    SBI-810 is a functionally selected β-arrestin-biased neurotensin receptor 1 (NTSR1) allosteric modulator. SBI-810 modulates NTSR1 G protein signaling in a G protein-specific manner in the presence of the endogenous ligand, neurotensin (NT). SBI-810 fully antagonizes NT-induced activation of Gq, partially antagonizes NT-induced activation of Gi1 and is permissive of NTSR1 activation of GoA and G12.
    SBI-810
  • HY-164814
    GPR27 agonist-1 651295-98-6 98%
    GPR27 Agonist-1 (compound I) is a selective GPR27 agonist with pEC50 of 6.34.
    GPR27 agonist-1
  • HY-164815
    S 8849-1 free base 104732-22-1 98%
    S 8849-1 (free base) (Tianeptine metabolite MC5) is a Tianeptine (HY-90003) metabolite that is found in plasma. The mean elimination half-lives of S 8849-1 (free base) is 7.53 h in rats. S 8849-1 (free base) is promising for research of antidepressants.
    S 8849-1 free base
Cat. No. Product Name / Synonyms Application Reactivity